Christophe GEX

Legal Counsel at ADC Therapeutics - Epalinges, Vaud, CH

Christophe GEX's Colleagues at ADC Therapeutics
Jay Feingold

Chief Medical Officer

Contact Jay Feingold

Jennifer Herron

Senior Vice President and Chief Commercial Officer

Contact Jennifer Herron

Jenn Creel

Chief Financial Officer

Contact Jenn Creel

John Iorio

Senior Manager, External Reporting

Contact John Iorio

Ashley Haney

Regulatory Operations Consultant

Contact Ashley Haney

Zhen Wu

Principal Scientist

Contact Zhen Wu

Julie Liu

Stability Scientist

Contact Julie Liu

View All Christophe GEX's Colleagues
Christophe GEX's Contact Details
HQ
+41 21 653 02 00
Location
Company
ADC Therapeutics
Christophe GEX's Company Details
ADC Therapeutics logo, ADC Therapeutics contact details

ADC Therapeutics

Epalinges, Vaud, CH • 325 Employees
BioTech/Drugs

ADC Therapeutics is a commercial-stage global pioneer in the field of antibody drug conjugates (ADCs). Our goal is to be a leading ADC company that transforms the lives of those impacted by cancer. To achieve this, we are focused on unlocking the potential value of our robust ADC portfolio across two pillars of growth: hematology and solid tumors. We are a pioneer in the ADC field with specialized end-to-end capabilities unique to ADCs including a validated technology platform, a growing next-generation research & development toolbox and a proven track record that includes an approved and marketed product. We aim to expand our portfolio and accelerate the development of our pipeline through targeted investments and in collaboration with strategic partners. In this way, we plan to pursue multiple targets in parallel, enabling us to prioritize and ensure disciplined capital allocation strategy while advancing the most promising candidates in both hematology and solid tumors. Our CD19-directed ADC ZYNLONTA® (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. Founded in 2011, ADC Therapeutics is based in Lausanne, Switzerland, with operations in London and New Jersey. Our highly skilled global team is committed to confronting cancer with the full potential of our science and transforming the treatment paradigm for patients with cancer. For more information, please visit https://www.adctherapeutics.com/.

Cancer Research Targeted Cancer Therapies Solid Tumors Molecular Oncology Biopharmaceuticals Healthcare Innovation Clinical Trials Biotechnology
Details about ADC Therapeutics
Frequently Asked Questions about Christophe GEX
Christophe GEX currently works for ADC Therapeutics.
Christophe GEX's role at ADC Therapeutics is Legal Counsel.
Christophe GEX's email address is ***@adctherapeutics.com. To view Christophe GEX's full email address, please signup to ConnectPlex.
Christophe GEX works in the BioTech/Drugs industry.
Christophe GEX's colleagues at ADC Therapeutics are Jay Feingold, Jennifer Herron, Jenn Creel, John Iorio, Ashley Haney, Zhen Wu, Julie Liu and others.
Christophe GEX's phone number is +41 21 653 02 00
See more information about Christophe GEX